The Oregon Department of Justice has also settled a case with Ranbaxy Laboratories Ltd. and two affiliated American companies. Pursuant to the settlement, $2.3 million will be paid to the state. It was discovered that Ranbaxy sold generic prescription drugs in Oregon that were not safe for consumers. A whistleblower case in federal court revealed that the company had been shipping substandard generic drugs to the United States, some of which were distributed in Oregon. While that case settled for $500 million, the money allocated to Oregon’s Medicaid program did not cover the full cost of drugs purchased from Ranbaxy.
The Ranbaxy-manufactured drugs in question include amoxicillin, a widely prescribed antibiotic; clavulanate potassium, used in combination with antibiotics to treat drug-resistant bacteria; and sotret, an acne medication. Medications manufactured by Ranbaxy have been subject to safety concerns outside of Oregon.